Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.69
+0.29 (3.92%)
At close: Jun 26, 2026, 4:00 PM EDT
7.66
-0.03 (-0.39%)
After-hours: Jun 26, 2026, 7:49 PM EDT

Xeris Biopharma Holdings Stock Forecast

Stock Price Forecast

The 3 analysts with 12-month price forecasts for Xeris Biopharma Holdings stock have an average target of 12.33, with a low estimate of 9.00 and a high estimate of 18. The average target predicts an increase of 60.34% from the current stock price of 7.69.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $9.00 $12.33 $10 $18
Change +17.04% +60.34% +30.04% +134.07%
* Price targets were last updated on May 14, 2026.

Analyst Ratings

The average analyst rating for Xeris Biopharma Holdings stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Dec '25Jan '26Mar '26Apr '26May '26Jun '26
Strong Buy 555555
Buy 111111
Hold 111111
Sell 000000
Strong Sell 000000
Total 777777

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Craig-Hallum
Craig-Hallum
Buy
Maintains
n/a
Buy Maintains n/a n/a Jun 11, 2026
Barclays
Barclays
Buy
Reiterates
$9
Buy Reiterates $9 +17.04% May 14, 2026
Unknown Analyst
Oppenheimer
No rating
Oppenheimer
Buy
Reiterates
$18
Buy Reiterates $18 +134.07% May 8, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$10
Buy Reiterates $10 +30.04% May 8, 2026
Unknown Analyst
Jefferies
No rating
Jefferies
Buy
Maintains
$10
Buy Maintains $10 +30.04% Jan 9, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
385.99M
from 291.85M
Increased by 32.26%
Revenue Next Year
472.82M
from 385.99M
Increased by 22.50%
EPS This Year
0.14
EPS Next Year
0.40
from 0.14
Increased by 177.19%
Fiscal Year FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
49.59M110.25M163.91M203.07M291.85M385.99M472.82M
Revenue Growth
142.67%122.32%48.68%23.89%43.72%32.26%22.50%
EPS
-1.55-0.70-0.45-0.370.000.110.34
EPS Growth
-----3,433.83%202.95%
Forward PE
-----67.8522.40
No. Analysts -----66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202620272028
High 389.5M 494.0M
Avg 386.0M 472.8M
Low 383.4M 451.2M

Revenue Growth

Revenue Growth 202620272028
High
33.5%
28.0%
Avg
32.3%
22.5%
Low
31.4%
16.9%

EPS Forecast

EPS 202620272028
High 0.19 0.60
Avg 0.14 0.40
Low 0.10 0.24

EPS Growth

EPS Growth 202620272028
High -
321.1%
Avg -
177.2%
Low -
68.4%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.